Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Myelodysplastic/Myeloproliferative Neoplasms

Children's Oncology Groupprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Myelodysplastic/Myeloproliferative Neoplasms cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BBB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BBB
Evomela
M.D. Anderson Cancer Center
Phase 2/3BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
Benadryl
Alliance for Clinical Trials in Oncology
Phase 2BB

View all 50 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →